CA2977539A1 - Sterol regulatory element-binding proteins (srebps) inhibitors - Google Patents

Sterol regulatory element-binding proteins (srebps) inhibitors Download PDF

Info

Publication number
CA2977539A1
CA2977539A1 CA2977539A CA2977539A CA2977539A1 CA 2977539 A1 CA2977539 A1 CA 2977539A1 CA 2977539 A CA2977539 A CA 2977539A CA 2977539 A CA2977539 A CA 2977539A CA 2977539 A1 CA2977539 A1 CA 2977539A1
Authority
CA
Canada
Prior art keywords
thiophen
piperidin
tert
methanone
butylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2977539A
Other languages
English (en)
French (fr)
Inventor
Brahmam PUJALA
Ramniwas JANGIR
Rambabu GUGULOTH
Bharat Uttam SHINDE
Roopa Rai
Son Minh Pham
Sebastian Bernales
Jeffrey Lindquist
Mausumee Guha
Satyanarayana KALLEM
Bhawana BHATT
Vikas Ramdas BHAGWAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Technologies LLC
Original Assignee
Medivation Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies LLC filed Critical Medivation Technologies LLC
Publication of CA2977539A1 publication Critical patent/CA2977539A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2977539A 2015-03-04 2016-03-04 Sterol regulatory element-binding proteins (srebps) inhibitors Abandoned CA2977539A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN615/DEL/2015 2015-03-04
IN615DE2015 2015-03-04
IN640DE2015 2015-03-09
IN640/DEL/2015 2015-03-09
PCT/US2016/020802 WO2016141258A1 (en) 2015-03-04 2016-03-04 Sterol regulatory element-binding proteins (srebps) inhibitors

Publications (1)

Publication Number Publication Date
CA2977539A1 true CA2977539A1 (en) 2016-09-09

Family

ID=55586426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977539A Abandoned CA2977539A1 (en) 2015-03-04 2016-03-04 Sterol regulatory element-binding proteins (srebps) inhibitors

Country Status (5)

Country Link
US (1) US10189826B2 (enExample)
EP (1) EP3265457A1 (enExample)
JP (1) JP2018507235A (enExample)
CA (1) CA2977539A1 (enExample)
WO (1) WO2016141258A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
EP3448851B8 (en) 2016-04-29 2022-04-27 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
CN112243374A (zh) 2018-01-29 2021-01-19 卡普勒斯疗法有限责任公司 包括6元中心环的srebp抑制剂
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP3917513A4 (en) * 2019-01-28 2022-11-09 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A THIOPHENE CENTER RING
JP2023502603A (ja) * 2019-11-13 2023-01-25 カピュラス セラピューティクス リミテッド ライアビリティ カンパニー 環状アミドを有するチオフェン化合物およびそれらの使用
AU2020381462A1 (en) * 2019-11-13 2022-06-02 Capulus Therapeutics, Llc SREBP inhibitor comprising a thiophene central ring
WO2021154735A1 (en) * 2020-01-27 2021-08-05 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
WO2022020738A1 (en) * 2020-07-24 2022-01-27 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
CN112225728A (zh) * 2020-08-18 2021-01-15 四川农业大学 一种多取代苯甲酰胺化合物及其制备方法和应用
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
CA2321025A1 (en) 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
CA2393821C (en) 1999-12-16 2009-05-26 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
TWI275589B (en) 2000-06-22 2007-03-11 Dow Agrosciences Llc 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
JP2008545767A (ja) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
AR054380A1 (es) 2005-06-09 2007-06-20 Schering Plough Ltd Control de parasitos en animales con derivados de n- ((feniloxi) fenil) -1,1,1-trifluorometansulfonamida y de n-(fenilsulfanil) fenil) -1,1,1-trifluorometansulfonamida
PT1907382E (pt) 2005-07-26 2015-09-25 Bial Portela & Ca Sa Derivados de nitrocatecol como inibidores de comt
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
AU2008214095B2 (en) * 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
WO2008114157A1 (en) * 2007-03-16 2008-09-25 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
US8202856B2 (en) 2007-12-21 2012-06-19 Merck Serono Sa Triazole oxadiazoles derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US20130040983A1 (en) 2010-01-08 2013-02-14 Jean-Michel Vernier Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
JP2014062047A (ja) 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
JP2015503505A (ja) 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
US20140364460A1 (en) 2012-01-18 2014-12-11 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
US20160193231A1 (en) 2013-06-26 2016-07-07 Rett Syndrome Research Trust Rett syndrome and treatments therefore
JP2017506618A (ja) 2013-08-28 2017-03-09 メディベイション テクノロジーズ， インコーポレイテッド 複素環式化合物および使用方法
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
US20180051013A1 (en) 2018-02-22
EP3265457A1 (en) 2018-01-10
JP2018507235A (ja) 2018-03-15
WO2016141258A1 (en) 2016-09-09
US10189826B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
CA2977539A1 (en) Sterol regulatory element-binding proteins (srebps) inhibitors
CA2584666C (en) Pyrimidine derivative condensed with a non-aromatic ring
US9303023B2 (en) Pyrazole and imidazole derivatives useful as orexin antagonists
JP2023529908A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
EP2640708A1 (en) Heterocycle amines and uses thereof
CA2935071A1 (en) Piperidine-dione derivatives
JP2023109962A (ja) Ｐｒｃ２阻害剤
DK3038622T3 (en) HETEROCYCLIC RELATIONS AND PROCEDURES FOR USE
CA2666973A1 (en) Indole compound having a glucokinase activating action
BR112016012146B1 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
US9102673B2 (en) Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
EP4561552A2 (en) Cdk2 inhibitors and methods of using the same
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US20250129100A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2024010762A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2023245137A1 (en) Slow skeletal troponin activators
CA2991404A1 (en) Imide derivatives and use thereof as medicine
KR20230155834A (ko) Ido/tdo 이중 저해용 화합물 및 이를 포함하는 약학적 조성물
WO2024193640A1 (zh) Cdk抑制剂
JP2025510009A (ja) Ｒｉｐ１調節物質、その調製、及び使用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210907

FZDE Discontinued

Effective date: 20210907